The Experts below are selected from a list of 12 Experts worldwide ranked by ideXlab platform
De Clercq E - One of the best experts on this subject based on the ideXlab platform.
-
Recent developments in herpesvirus therapy.
Herpes : the journal of the IHMF, 2001Co-Authors: Lieve Naesens, De Clercq EAbstract:The antiherpes drugs aciclovir and ganciclovir are considered the standard treatments and prophylactic agents for infections caused by herpes simplex virus (HSV) varicella zoster virus (VZV) and cytomegalovirus (CMV). Until a decade ago the impact of aciclovir on the control of severe and life-threatening herpesvirus infections was unprecedented. During the past few years we have witnessed approval of new therapeutic drugs for infections caused by HSV and VZV (i.e. penciclovir and the oral prodrugs valaciclovir and famciclovir) CMV (i.e. ganciclovir cidofovir and fomivirsen) or HSV VZV and CMV (i.e. foscarnet). A few agents such as brivudin and Benzimidavir are in ongoing clinical development; others have been suspended because of safety concerns. New antiherpes agents are needed to face clinical issues such as drug resistance increased use of antiherpes prophylaxis in transplantation and safety concerns in small children or pregnant women. (authors)
Lieve Naesens - One of the best experts on this subject based on the ideXlab platform.
-
Recent developments in herpesvirus therapy.
Herpes : the journal of the IHMF, 2001Co-Authors: Lieve Naesens, De Clercq EAbstract:The antiherpes drugs aciclovir and ganciclovir are considered the standard treatments and prophylactic agents for infections caused by herpes simplex virus (HSV) varicella zoster virus (VZV) and cytomegalovirus (CMV). Until a decade ago the impact of aciclovir on the control of severe and life-threatening herpesvirus infections was unprecedented. During the past few years we have witnessed approval of new therapeutic drugs for infections caused by HSV and VZV (i.e. penciclovir and the oral prodrugs valaciclovir and famciclovir) CMV (i.e. ganciclovir cidofovir and fomivirsen) or HSV VZV and CMV (i.e. foscarnet). A few agents such as brivudin and Benzimidavir are in ongoing clinical development; others have been suspended because of safety concerns. New antiherpes agents are needed to face clinical issues such as drug resistance increased use of antiherpes prophylaxis in transplantation and safety concerns in small children or pregnant women. (authors)
Hermann Einsele - One of the best experts on this subject based on the ideXlab platform.
-
Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell Transplantation
Drugs, 1998Co-Authors: Holger Hebart, Lothar Kanz, Gerhard Jahn, Hermann EinseleAbstract:Recent developments in diagnosis and therapy of cytomegalovirus (CMV) infection have helped to reduce CMV-associated mortality following organ transplantation. However, CMV is still associated with significant morbidity in recipients of an allogeneic stem cell or solid-organ transplant. The clinical symptoms of active CMV infection per se and, most importantly, the prevalence of life-threatening CMV disease show broad variation between different patient populations depending on the type of transplant and the intensity of immunosuppression. Therefore, management of CMV infection must be stratified according to risk profiles of a given patient population. In the past decade, novel diagnostic assays (such as rapid shell-vial culture, polymerase chain reaction, pp65 antigen assay and sensitive hybridisation techniques) have been developed. Broad variations in the ability of a given test to predict a positive or negative risk of developing CMV disease have been observed between different transplant modalities. Highly effective therapeutic agents against CMV, such as ganciclovir and foscarnet, have become available, improving the outcome of patients with CMV disease. Moreover, antiviral prophylaxis with ganciclovir or aciclovir has been shown to reduce CMV infection and CMV disease following organ transplantation. However, these drugs are often associated with considerable toxicity. Moreover, antiviral resistance to ganciclovir and foscarnet has been observed in recipients of organ transplants and, even more frequently, in patients with AIDS. Short courses of pre-emptive antiviral therapy, administered after CMV infection has been documented by sensitive diagnostic techniques prior to the development of clinical symptoms, help to reduce duration and incidence of adverse effects associated with antiviral drugs and are thus an attractive alternative strategy compared with antiviral prophylaxis. Newer options, such as oral ganciclovir, cidofovir, Benzimidavir (1263W94) and lobucavir, are currently under investigation and might further improve the management of CMV infection in recipients of solid-organ or stem-cell transplants.
Holger Hebart - One of the best experts on this subject based on the ideXlab platform.
-
Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell Transplantation
Drugs, 1998Co-Authors: Holger Hebart, Lothar Kanz, Gerhard Jahn, Hermann EinseleAbstract:Recent developments in diagnosis and therapy of cytomegalovirus (CMV) infection have helped to reduce CMV-associated mortality following organ transplantation. However, CMV is still associated with significant morbidity in recipients of an allogeneic stem cell or solid-organ transplant. The clinical symptoms of active CMV infection per se and, most importantly, the prevalence of life-threatening CMV disease show broad variation between different patient populations depending on the type of transplant and the intensity of immunosuppression. Therefore, management of CMV infection must be stratified according to risk profiles of a given patient population. In the past decade, novel diagnostic assays (such as rapid shell-vial culture, polymerase chain reaction, pp65 antigen assay and sensitive hybridisation techniques) have been developed. Broad variations in the ability of a given test to predict a positive or negative risk of developing CMV disease have been observed between different transplant modalities. Highly effective therapeutic agents against CMV, such as ganciclovir and foscarnet, have become available, improving the outcome of patients with CMV disease. Moreover, antiviral prophylaxis with ganciclovir or aciclovir has been shown to reduce CMV infection and CMV disease following organ transplantation. However, these drugs are often associated with considerable toxicity. Moreover, antiviral resistance to ganciclovir and foscarnet has been observed in recipients of organ transplants and, even more frequently, in patients with AIDS. Short courses of pre-emptive antiviral therapy, administered after CMV infection has been documented by sensitive diagnostic techniques prior to the development of clinical symptoms, help to reduce duration and incidence of adverse effects associated with antiviral drugs and are thus an attractive alternative strategy compared with antiviral prophylaxis. Newer options, such as oral ganciclovir, cidofovir, Benzimidavir (1263W94) and lobucavir, are currently under investigation and might further improve the management of CMV infection in recipients of solid-organ or stem-cell transplants.
Lothar Kanz - One of the best experts on this subject based on the ideXlab platform.
-
Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell Transplantation
Drugs, 1998Co-Authors: Holger Hebart, Lothar Kanz, Gerhard Jahn, Hermann EinseleAbstract:Recent developments in diagnosis and therapy of cytomegalovirus (CMV) infection have helped to reduce CMV-associated mortality following organ transplantation. However, CMV is still associated with significant morbidity in recipients of an allogeneic stem cell or solid-organ transplant. The clinical symptoms of active CMV infection per se and, most importantly, the prevalence of life-threatening CMV disease show broad variation between different patient populations depending on the type of transplant and the intensity of immunosuppression. Therefore, management of CMV infection must be stratified according to risk profiles of a given patient population. In the past decade, novel diagnostic assays (such as rapid shell-vial culture, polymerase chain reaction, pp65 antigen assay and sensitive hybridisation techniques) have been developed. Broad variations in the ability of a given test to predict a positive or negative risk of developing CMV disease have been observed between different transplant modalities. Highly effective therapeutic agents against CMV, such as ganciclovir and foscarnet, have become available, improving the outcome of patients with CMV disease. Moreover, antiviral prophylaxis with ganciclovir or aciclovir has been shown to reduce CMV infection and CMV disease following organ transplantation. However, these drugs are often associated with considerable toxicity. Moreover, antiviral resistance to ganciclovir and foscarnet has been observed in recipients of organ transplants and, even more frequently, in patients with AIDS. Short courses of pre-emptive antiviral therapy, administered after CMV infection has been documented by sensitive diagnostic techniques prior to the development of clinical symptoms, help to reduce duration and incidence of adverse effects associated with antiviral drugs and are thus an attractive alternative strategy compared with antiviral prophylaxis. Newer options, such as oral ganciclovir, cidofovir, Benzimidavir (1263W94) and lobucavir, are currently under investigation and might further improve the management of CMV infection in recipients of solid-organ or stem-cell transplants.